Risk factor Identification and Assessment in Hypertension and Diabetes (RIAHD) study

Blood Pressure

Volumn 15, Issue 6, 2006, Pages 367-374

  Skrtic, S ^a   Niklason, A ^a   Leoo, T ^a   Hedner, T ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Cardiovascular; Diabetes; Hypertension; Microalbuminuria; Risk factor; Viscosity

Indexed keywords

C REACTIVE PROTEIN; CHOLESTEROL; FIBRINOGEN;

AGED; AMBULATORY CARE; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD VISCOSITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTROLLED STUDY; CORONARY RISK; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DISEASE MARKER; DNA POLYMORPHISM; FEMALE; HEALTH CARE UTILIZATION; HEALTH ECONOMICS; HIGH RISK POPULATION; HOME MONITORING; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEDICAL LEAVE; MICROALBUMINURIA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REFERENCE VALUE; RISK ASSESSMENT; SCORING SYSTEM; SYSTOLIC BLOOD PRESSURE;

ABSENTEEISM; AGED; ALBUMINURIA; ANTHROPOMETRY; BLOOD PRESSURE MONITORING, AMBULATORY; BLOOD PROTEINS; BLOOD VISCOSITY; CARDIOVASCULAR DISEASES; COHORT STUDIES; COST OF ILLNESS; DIABETES MELLITUS; FEMALE; HEALTH SERVICES; HUMANS; HYPERTENSION; LIPIDS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; RISK ASSESSMENT; RISK FACTORS; SWEDEN;

EID: 33847242951     PISSN: 08037051     EISSN: 16511999     Source Type: Journal    
DOI: 10.1080/08037050601103984     Document Type: Article

References (31)

1. Murray, C. J. and Lopez, A. D. (1997) Regional patterns of disability-free life expectancy and disability-adjusted life expectancy: Global Burden of Disease Study. Lancet, 349, pp. 1347-1352.
2. Murray, C. J. and Lopez, A. D. (1997) Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet, 349, pp. 1436-1442.
3. (2003) 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens, 21, pp. 1011-1053.
4. Cederholm, J., Eliasson, B., Nilsson, P. M., Weiss, L., Gudbjornsdottir, S. and Steering Committee of the Swedish National Diabetes Register (2005) Microalbuminuria and risk factors in type 1 and type 2 diabetic patients. Diabetes Res Clin Pract, 67, pp. 258-266.
5. Dinneen, S. F. and Gerstein, H. C. (1997) The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus: A systematic overview of the literature. Arch Intern Med, 157, pp. 1413-1418.
6. Chalmers, J., MacMahon, S., Mancia, G., Whitworth, J., Beilin, L. and Hansson, L. (1999) 1999 World Health Organization-International Society of Hypertension Guidelines for the management of hypertension. Guidelines sub-committee of the World Health Organization. Clin Exp Hypertens, 21, pp. 1009-1060.
7. Parving, H. H., Lehnert, H., Brochner-Mortensen, J., Gomis, R., Andersen, S., Arner, P. and Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group (2001) The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med, 345, pp. 870-878.
8. Eliasson, B., Cederholm, J., Nilsson, P., Gudbjornsdottir, S. and Steering Committee of the Swedish National Diabetes Register (2005) The gap between guidelines and reality: Type 2 diabetes in a National Diabetes Register 1996-2003. Diabet Med, 22, pp. 1420-1426.
9. Hussain, M. A., Kar, S. and Puniyani, R. R. (1999) Relationship between power law coefficients and major blood constituents affecting the whole blood viscosity. J Biosciences, 24, pp. 329-337.
10. Hussain, M. A., Puniyani, R. R. and Kar, S. (1899) 1994 Quantification of blood viscosity using power law model in cerebrovascular accidents and high risk controls: Clin. Hemorheol, 14, pp. 685-696.
11. Nilsson, P. M., Cederholm, J., Gudbjornsdottir, S., Eliasson, B. and Steering Committee of the National Diabetes Register of Sweden (2005) Predictors of successful long-term blood pressure control in type 2 diabetic patients: Data from the Swedish National Diabetes Register (NDR). J Hypertens, 23, pp. 2305-2311.
12. Lowe, G. D., Rumley, A., Whincup, P. H. and Danesh, J. (2002) Hemostatic and rheological variables and risk of cardiovascular disease. Semin Vasc Med, 2, pp. 429-439.
13. Moriarty, P. M. and Gibson, C. A. (2005) Association between hematological parameters and high-density lipoprotein cholesterol. Curr Opin Cardiol, 20, pp. 318-323.
14. Kannel, W. B., Wolf, P. A., Castelli, W. P. and D'Agostino, R. B. (1987) Fibrinogen and risk of cardiovascular disease. The Framingham Study. JAMA, 258, pp. 1183-1186.
15. Kannel, W. B. (2005) Overview of hemostatic factors involved in atherosclerotic cardiovascular disease. Lipids, 40, pp. 1215-1220.
16. Cuspidi, C., Meani, S., Salerno, M., Severgnini, B., Fusi, V. and Valerio, C. (2004) Cardiovascular risk stratification according to the 2003 ESH-ESC guidelines in uncomplicated patients with essential hypertension: Comparison with the 1999 WHO/ISH guidelines criteria. Blood Press, 13, pp. 144-151.
17. Winocour, P. H. and Fisher, M. (2003) Prediction of cardiovascular risk in people with diabetes. Diabet. Med, 20, pp. 515-527.
18. Montgomery, A. A., Fahey, T., MacKintosh, C., Sharp, D. J. and Peters, T. J. (2000) Estimation of cardiovascular risk in hypertensive patients in primary care. Br J Gen Pract, 50, pp. 127-128.
19. Meland, E., Laerum, E. and Stensvold, I. (1994) Assessment of coronary heart disease risk, I. A postal inquiry among primary care physicians. Fam Pract, 11, pp. 117-121.
20. Grover, S. A., Lowensteyn, I., Esrey, K. L., Steinert, Y., Joseph, L. and Abrahamowicz, M. (1995) Do doctors accurately assess coronary risk in their patients? Preliminary results of the coronary health assessment study. BMJ, 310, pp. 975-978.
21. Stephens, J. W., Ambler, G., Vallance, P., Betteridge, D. J., Humphries, S. E. and Hurel, S. J. (2004) Cardiovascular risk and diabetes. Are the methods of risk prediction satisfactory? Clinical Practise and Education Paper. Eur J Cardiovasc Prev Rehabil, 11, pp. 521-528.
22. van Wyk, J. T., van Wijk, M. A., Sturkenboom, M. C., Moorman, P. W. and van der Lei, J. (2005) Identification of the four conventional cardiovascular disease risk factors by Dutch general practitioners. Chest, 128, pp. 2521-2527.
23. Khot, U. N., Khot, M. B., Bajzer, C. T., Sapp, S. K., Ohman, E. M. and Brener, S. J. (2003) Prevalence of conventional risk factors in patients with coronary heart disease. JAMA, 290, pp. 898-904.
24. Greenland, P., Knoll, M. D., Stamler, J., Neaton, J. D., Dyer, A. R. and Garside, D. B. (2003) Major risk factors as antecedents of fatal and nonfatal coronary heart disease events. JAMA, 290, pp. 891-897.
25. Jacobson, T. A. (2000) "The lower the better"in hypercholesterolemia therapy: A reliable clinical guideline?. Ann Intern Med, 133, pp. 549-554.
26. Onat, A., Soydan, I., Tokgozoglu, L., Sansoy, V., Koylan, N. and Domanic, N. (2003) Guideline implementation in a multicenter study with an estimated 44% relative cardiovascular event risk reduction. Clin Cardiol, 26, pp. 243-249.
27. Saydah, S. H., Fradkin, J. and Cowie, C. C. (2004) Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA, 291, pp. 335-342.
28. Alzahrani, T., Marrat, S. and Haider, A. (2003) Management of dyslipidemia in primary care. Can J Cardiol, 19, pp. 1499-1502.
29. Lenfant, C. (2003) Shattuck lecture: Clinical research to clinical practice; Lost in translation?. N Engl J Med, 349, pp. 868-874.
30. Brady, A. J. B., Oliver, M. A. and Pittard, J. B. (2001) Secondary prevention in 24,431 patients with coronary heart disease: Survey in primary care. BMJ, 322, p. 1463.
31. Fox, J. and Jones, K. (2001) Lipid-lowering interventions in managed care settings. Am J Med, 110, pp. 24-30.